Evidence map›Paper›PMID 39871064›Full record

SynthesisNeurosurgical review2025

Safety and efficacy of tirofiban in the endovascular treatment of intracranial aneurysms: a systematic evaluation and meta-analysis.

ZhenKun Xiao, Bing Wang, YiBo Yang, MingJia Huang, JianHua Liu, YongHong Duan, AiHua Liu

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

ZhenKun XiaoHengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421000, Hunan, China.
Bing WangHengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421000, Hunan, China.
YiBo YangHengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421000, Hunan, China.
MingJia HuangHengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421000, Hunan, China.
JianHua LiuMedical Teaching Experiment Center, Medical School, ShenZhen University, ShenZhen, China.
YongHong DuanHengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421000, Hunan, China. duanyonghong999@163.com.
AiHua LiuHengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421000, Hunan, China. 16673498449@163.com.

Funding

Hunan Nature Science Foundation 2023JJ30531the Natural Science Foundation of China 81771233, 82171290the Technology Innovation Guidance Program of Science and Technology, Department of Hunan Province 2020SK51708
6 · The paper itself

Abstract

Patients with intracranial aneurysms (IA) undergoing endovascular treatment face varying risks and benefits when tirofiban is used for thromboprophylaxis during surgery. Currently, there is a lack of high-level evidence summarizing this information. This study aims to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of tirofiban during endovascular treatment of IA. Relevant studies published before November 2024 were searched in the PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials databases. The primary outcomes were intracranial hemorrhage (ICH), thrombosis, and thrombolysis. Secondary outcomes included any non-ICH bleeding events (NoICH-BE), ischemic stroke (IS), intraoperative rupture aneurysm(IRA), follow-up prognosis, and Raymond and Roy classification (RROC). Meta-analysis was performed using Revman 5.3 and StataMP 64 to assess efficacy (thrombosis, IS, thrombolysis) and safety (ICH, NoICH-BE, IRA). A total of 33 studies involving 3,617 IA patients were included. The meta-analysis showed that after the use of tirofiban, the pooled risk (PR) for ICH was 2% ([95% CI, 1-3%]; P < 0.001), for NoICH-BE was 0% ([95% CI, 0-2%]; P > 0.05), for IRA was 2% ([95% CI, 1-3%]; P < 0.001), for thrombosis was 3% ([95% CI, 2-4%]; P < 0.001), for IS was 2% ([95% CI, 0-3%]; P < 0.001), for thrombolysis was 96% ([95% CI, 91-99%]; P < 0.001), for good prognosis (mRS 0-2) was 91% ([95% CI, 85-95%]; P < 0.001), and for RROC 1-2 was 93% ([95% CI, 90-96%]; P < 0.001). This systematic review and meta-analysis demonstrate that the use of tirofiban during endovascular treatment of IA is both feasible and safe.

Indexed as

Endovascular ProceduresFibrinolytic AgentsIntracranial AneurysmPlatelet Aggregation InhibitorsTirofibanFeasibility StudiesHumansTreatment OutcomeFibrinolytic AgentsPlatelet Aggregation InhibitorsTirofibanEndovascular treatmentIntracranial aneurysmsIntracranial hemorrhageThrombosisTirofiban

Identifiers

PMID39871064

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.